Create a Profile
Create a Profile
Get In Touch Mobile
Accel Research Sites now enrolling for Alzheimer’s study evaluating sensory simulation as potential treatment
People living with memory loss encouraged to learn more about unique research opportunity.
Accel Research Sites is now enrolling volunteers for a unique Alzheimer’s disease research study investigating the effectiveness of a wearable device to possibly help slow the progression of cognitive decline in people living with Alzheimer’s using sensory stimulation.
The study, known as HOPE, evaluates a device that incorporates eyewear and headphones that may help people who are in the early or moderate stages of the disease.
“For people who have received an Alzheimer’s disease diagnosis but may have never participated in clinical research trials, this study gives them a way to get involved,” said Dr. Marshall L. Nash, principal investigator of the study. “Where some people may have concerns about taking new medicines or undergoing medical procedures, this study is as simple as wearing a headset for an hour a day.”
The device is called CogTx-001 and was developed by Cognito Therapeutics. It works by delivering a sensory treatment in the form of mild pulsing light and sound. The study evaluates how effective the treatment is at stimulating immune cells to clear out proteins associated with Alzheimer’s disease.
Study volunteers wear the device, which looks like a combination of headphones and wraparound sunglasses, at home for an hour a day for up to 12 months.
Accel Research Sites is looking for volunteers who meet the following qualifications:
- Between the ages of 50 and 85
- Have experienced memory loss
- Have a friend or family member who can participate as a study partner with a daily visit for up to one hour
Nationwide, the HOPE study seeks to enroll around 345 volunteers. Along with Accel Research Sites, several other clinical research centers throughout the U.S. are participating in the study in partnership with the Global Alzheimer’s Platform Foundation® (GAP) and its network of research sites (GAP-Net).
GAP-Net sites benefit from sharing knowledge and experience to advance research and treatment for Alzheimer’s and other neurodegenerative diseases.
“GAP is always looking to participate in studies searching for innovative treatments and therapies for those living with Alzheimer’s disease, and Cognito’s wearable device provides another potential treatment option,” said GAP President John Dwyer. “This is an exciting opportunity for people who have experienced memory loss are interested in a new kind of clinical research opportunity.”
For more information about the HOPE study and how to participate, visit HopeStudyForAD.com/GAP.
Ready to be part of healthcare history? Find the right clinical trial for you.